World Journal of Gastroenterology, Год журнала: 2024, Номер 30(36), С. 4036 - 4043

Опубликована: Сен. 20, 2024

This editorial takes a deeper look at the insights provided by Soresi and Giannitrapani, which examined therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for metabolic dysfunction-associated fatty liver disease. We provide supplementary to their research, highlighting broader systemic implications GLP-1RAs, synthesizing current understanding mechanisms trajectory research in this field. GLP-1RAs are revolutionizing treatment type 2 diabetes mellitus beyond. Beyond glycemic control, demonstrate cardiovascular renal protective effects, offering managing diabetic kidney disease al-ongside renin–angiotensin–aldosterone system inhibitors. Their role bone metabolism hints benefits osteoporosis, while neuroprotective properties show promise Alzheimer's modulating neuronal insulin signaling. Additionally, they improve hormonal profiles polycystic ovary syndrome. highlights multifaceted emphasizing need ongoing fully realize across range multisystemic diseases.

Язык: Английский